Infliximab biosimilar (Hisun Pharma)

英夫利西单抗生物类似药（海正药业）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInfliximab biosimilar (Hisun Pharma)
Drug Alias NameRecombinant chimeric anti-TNFα antibody (Hisun Pharma)重组人鼠嵌合抗肿瘤坏死因子α单抗（海正药业）英夫利昔单抗生物类似药（海正药业）HS-626
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasis
Global Approved IndicationsPsoriasis
Approved Indications in ChinaPsoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2021/09/24
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHisun Biopharmaceutical Co Ltd
Inactive CompaniesZhejiang Hisun Pharmaceutical Co LtdHisun Pharmaceutical (Hangzhou) Co Ltd
Active IndicationsPsoriasis
Inactive IndicationsPlaque psoriasis

Other Information

ATC CodeN/A
Related LinksN/A